Drug Information

Drug General Information
Drug ID
D0A4TC
Former ID
DNC000955
Drug Name
MMI270
Drug Type
Small molecular drug
Indication Discovery agent Investigative [1]
Structure
Download
2D MOL

3D MOL
Formula
C18H23N3O5S
Canonical SMILES
CC(C)C(C(=O)NO)N(CC1=CN=CC=C1)S(=O)(=O)C2=CC=C(C=C2)OC
InChI
1S/C18H23N3O5S/c1-13(2)17(18(22)20-23)21(12-14-5-4-10-19-11-14)27(24,25)16-8-6-15(26-3)7-9-16/h4-11,13,17,23H,12H2,1-3H3,(H,20,22)/t17-/m1/s1
InChIKey
BSIZUMJRKYHEBR-QGZVFWFLSA-N
PubChem Compound ID
446504
PubChem Substance ID
835264, 835589, 7885288, 7886571, 10299905, 11109211, 14780888, 14830102, 36888902, 46391557, 46391831, 57280005, 57404747, 75458863, 81063758, 99444027, 103165103, 103961278, 104636574, 127561235, 134340236, 134347923, 137098396, 142466817, 160649712, 160968629, 170481306, 196409719, 224991313, 229481470
Target and Pathway
Target(s) Neutrophil collagenase Target Info Inhibitor [2]
Carbonic anhydrase IX Target Info Inhibitor [3]
MMP-9 Target Info Inhibitor [4]
Matrilysin Target Info Inhibitor [5]
Interstitial collagenase Target Info Inhibitor [6]
ADAMTS-4 Target Info Inhibitor [1]
72 kDa type IV collagenase Target Info Inhibitor [4]
Matrix metalloproteinase-14 Target Info Inhibitor [5]
Carbonic anhydrase II Target Info Inhibitor [3]
Collagenase 3 Target Info Inhibitor [7]
Lethal factor Target Info Inhibitor [6]
Stromelysin-1 Target Info Inhibitor [8]
KEGG Pathway Nitrogen metabolismhsa04668:TNF signaling pathway
Leukocyte transendothelial migration
Estrogen signaling pathway
Hepatitis B
Pathways in cancer
Transcriptional misregulation in cancer
Proteoglycans in cancer
MicroRNAs in cancer
Bladder cancerhsa04310:Wnt signaling pathwayhsa03320:PPAR signaling pathway
Bladder cancer
Rheumatoid arthritishsa04670:Leukocyte transendothelial migration
GnRH signaling pathway
Bladder cancerhsa04668:TNF signaling pathway
GnRH signaling pathwayhsa00910:Nitrogen metabolism
Proximal tubule bicarbonate reclamation
Collecting duct acid secretion
Gastric acid secretion
Pancreatic secretion
Bile secretionhsa04668:TNF signaling pathway
Rheumatoid arthritis
NetPath Pathway ID Signaling Pathway
TWEAK Signaling Pathway
Leptin Signaling Pathway
TNFalpha Signaling PathwayNetPath_8:Wnt Signaling PathwayNetPath_13:IL1 Signaling Pathway
EGFR1 Signaling Pathway
Wnt Signaling PathwayNetPath_22:Leptin Signaling Pathway
TCR Signaling Pathway
ID Signaling PathwayNetPath_16:IL4 Signaling Pathway
EGFR1 Signaling PathwayNetPath_13:IL1 Signaling PathwayNetPath_13:IL1 Signaling Pathway
IL4 Signaling Pathway
PANTHER Pathway Alzheimer disease-presenilin pathwayP00004:Alzheimer disease-presenilin pathway
Plasminogen activating cascade
CCKR signaling map STP00004:Alzheimer disease-presenilin pathway
Wnt signaling pathway
Plasminogen activating cascadeP00004:Alzheimer disease-presenilin pathwayP00004:Alzheimer disease-presenilin pathwayP00004:Alzheimer disease-presenilin pathway
Plasminogen activating cascadeP00050:Plasminogen activating cascade
CCKR signaling map ST
Pathway Interaction Database HIF-1-alpha transcription factor networklysophospholipid_pathway:LPA receptor mediated events
Plasma membrane estrogen receptor signaling
Osteopontin-mediated events
Validated transcriptional targets of AP1 family members Fra1 and Fra2
Validated targets of C-MYC transcriptional activation
CXCR4-mediated signaling events
amb2 Integrin signaling
Syndecan-4-mediated signaling events
AP-1 transcription factor network
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
Syndecan-1-mediated signaling events
Regulation of nuclear beta catenin signaling and target gene transcription
FGF signaling pathwayajdiss_2pathway:Posttranslational regulation of adherens junction stability and dissassembly
p75(NTR)-mediated signaling
Syndecan-1-mediated signaling eventsendothelinpathway:Endothelins
Glucocorticoid receptor regulatory network
Syndecan-1-mediated signaling eventslysophospholipid_pathway:LPA receptor mediated events
Angiopoietin receptor Tie2-mediated signaling
Direct p53 effectors
ATF-2 transcription factor network
FOXM1 transcription factor network
Syndecan-2-mediated signaling eventshif2pathway:HIF-2-alpha transcription factor network
Signaling events mediated by focal adhesion kinaseupa_upar_pathway:Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalinganthraxpathway:Cellular roles of Anthrax toxinajdiss_2pathway:Posttranslational regulation of adherens junction stability and dissassembly
Reactome Collagen degradation
Degradation of the extracellular matrix
Activation of Matrix MetalloproteinasesR-HSA-1234158:Regulation of gene expression by Hypoxia-inducible Factor
Reversible hydration of carbon dioxideR-HSA-1442490:Collagen degradation
Activation of Matrix Metalloproteinases
Assembly of collagen fibrils and other multimeric structures
EPH-ephrin mediated repulsion of cellsR-HSA-1442490:Collagen degradation
Assembly of collagen fibrils and other multimeric structuresR-HSA-1442490:Collagen degradation
Basigin interactions
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)R-HSA-1474228:Degradation of the extracellular matrix
O-glycosylation of TSR domain-containing proteinsR-HSA-1442490:Collagen degradation
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
Activation of Matrix MetalloproteinasesR-HSA-1237044:Erythrocytes take up carbon dioxide and release oxygen
Erythrocytes take up oxygen and release carbon dioxide
Assembly of collagen fibrils and other multimeric structuresR-HSA-5210891:Uptake and function of anthrax toxinsR-HSA-1442490:Collagen degradation
EGFR Transactivation by Gastrin
WikiPathways Activation of Matrix Metalloproteinases
Matrix MetalloproteinasesWP2877:Vitamin D Receptor Pathway
Reversible Hydration of Carbon Dioxide
Regulation of Hypoxia-inducible Factor (HIF) by OxygenWP474:Endochondral Ossification
IL1 and megakaryotyces in obesity
Mammary gland development pathway - Involution (Stage 4 of 4)
Degradation of collagen
Spinal Cord Injury
AGE/RAGE pathway
TWEAK Signaling Pathway
Angiogenesis
Osteopontin Signaling
Matrix MetalloproteinasesWP399:Wnt Signaling Pathway and Pluripotency
Matrix MetalloproteinasesWP366:TGF beta Signaling Pathway
Bladder Cancer
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
Oncostatin M Signaling Pathway
Prostate Cancer
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Cell surface interactions at the vascular wall
Matrix MetalloproteinasesWP474:Endochondral OssificationWP2769:Activation of Matrix Metalloproteinases
Matrix MetalloproteinasesWP615:Senescence and Autophagy in Cancer
Matrix MetalloproteinasesWP2770:Reversible Hydration of Carbon Dioxide
Uptake of Carbon Dioxide and Release of Oxygen by Erythrocytes
Uptake of Oxygen and Release of Carbon Dioxide by ErythrocytesWP474:Endochondral Ossification
Matrix MetalloproteinasesWP2769:Activation of Matrix Metalloproteinases
Gastrin-CREB signalling pathway via PKC and MAPK
Matrix Metalloproteinases
References
REF 1Bioorg Med Chem Lett. 2006 Jan 15;16(2):311-6. Epub 2005 Nov 3.Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors.
REF 2J Med Chem. 1999 Nov 4;42(22):4547-62.Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
REF 3Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. Epub 2007 Jan 19.Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I andII with sulfonylated hydroxamates.
REF 4Bioorg Med Chem Lett. 1999 Jun 21;9(12):1691-6.Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
REF 5Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. Epub 2006 Nov 14.Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.
REF 6Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8. Epub 2005 Dec 9.The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.
REF 7Bioorg Med Chem Lett. 2001 Apr 23;11(8):1009-13.Heterocycle-based MMP inhibitors with P2' substituents.
REF 8Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.